In recent years, the traditional method of producing flu vaccines using chicken eggs has been a standard practice. Despite its long-standing history since the 1940s, scientists are now exploring more advanced techniques for vaccine development.
While the egg-based system has proven effective in producing millions of influenza vaccines annually, challenges such as supply shortages and potential issues associated with eggs have prompted researchers to seek alternative solutions. The World Health Organization biannually determines the optimal vaccine composition based on prevalent strains, a process that can take up to six months to complete.
However, this approach can lead to delays in adapting to rapidly mutating viruses, potentially rendering last year’s vaccine less effective against the current strain. Given the contagious nature of the flu, which can cause a range of symptoms from mild to severe complications like pneumonia, enhancing vaccine efficiency is crucial.
A significant breakthrough in vaccine development was recently reported in a Phase 3 clinical trial published in the New England Journal of Medicine. Pfizer’s mRNA flu shot demonstrated 34% higher efficacy compared to traditional egg-based vaccines in a study involving over 18,000 adults across different regions during the 2022–23 flu season.
While the mRNA vaccine showed promising results, it was associated with more mild to moderate side effects like fever and redness compared to conventional vaccines. Despite this, experts view this advancement as a critical step forward in vaccine innovation.
In addition to mRNA vaccines, cell-based flu vaccines grown in animal cells are gaining traction as a faster and potentially more efficient alternative to egg-based production. Although cell-based vaccines offer advantages in speed, they come at a higher cost. Dr. Barry Pakes emphasized the importance of onshoring vaccine manufacturing to ensure a stable vaccine supply.
Another innovative approach involves recombinant vaccines made in insect cells, offering a faster production process. These advancements present a diverse range of vaccine options with unique benefits and drawbacks, highlighting the ongoing efforts to enhance flu vaccine effectiveness and accessibility.
Looking ahead, ongoing research aims to develop improved vaccine technologies, such as aerosolized vaccines for better and longer-lasting protection against seasonal and pandemic influenza viruses. While egg-based vaccines have served well historically, the evolving landscape of vaccine development underscores the importance of exploring novel approaches to combat influenza effectively.